论文部分内容阅读
目的探讨苦参碱预处理对大鼠缺血/再灌注肝损伤(HIRI)的保护作用及其机制。方法健康成年雄性SD大鼠75只,随机分为5组,每组15只,15只作为空白对照组(SO组),不阻断肝脏血流;60只以夹闭门静脉和肝动脉缺血70 min后进行再灌注方法建立HIRI模型,然后再分为4组,分别为模型组即缺血/再灌注+生理盐水组(NS组)、缺血/再灌注+苦参碱组(MT组),MT组依剂量不同分别为MT1、MT2、MT3组(苦参碱剂量分别为7.5、15.0、30.0 mg/kg),MT组在夹闭门静脉和肝动脉前经门静脉主干注入苦参碱。NS组注入生理盐水,阻断供血70 min后恢复灌注,在恢复灌注2 h后采集相关标本待测。检测各组大鼠肝功能指标,包括血清丙氨酸氨基转移酶(ALT)、天门冬氨酸氨基转移酶(AST)、乳酸脱氢酶(LDH)及肝组织匀浆中TNF-α的含量,同时观察肝组织病理形态学改变。结果病理组织学检查显示MT组肝细胞损伤程度较模型组轻,且MT3组最轻;模型组肝功能指标明显高于SO组及MT各组(P均<0.01);MT各组中,MT1组明显高于MT3组(P<0.05或P<0.01),即苦参碱与肝功能指标下降存在剂量效应关系。SO组肝组织中TNF-α含量较少为(54.76±11.32)pg/mg·prot,模型组TNF-α含量最高为(2 175.67±131.64)pg/mg·prot,MT1含量为(1 664.47±109.21)pg/mg·prot,MT2含量为(1 561.52±104.52)pg/mg·prot,MT3含量为(1 245.17±96.69)pg/mg·prot,MT各组随剂量增加TNF-α含量降低,3组与模型组比较差异均有统计学意义(P均<0.05),MT3组低于MT1、MT2(P均<0.05)。结论苦参碱对缺血/再灌注中肝细胞损伤有保护作用,且存在剂量相关性,其机制可能与苦参碱抑制TNF-α释放有关。
Objective To investigate the protective effect and mechanism of matrine preconditioning on ischemia / reperfusion injury in rats (HIRI). Methods Seventy five healthy male Sprague-Dawley rats were randomly divided into 5 groups (15 rats in each group) and 15 rats in control group (SO group), without blockage of hepatic blood flow. Sixty male Sprague Dawley rats The HIRI model was established after reperfusion for 70 min and then divided into 4 groups: ischemia / reperfusion + saline group (NS group), ischemia / reperfusion + matrine group MT group MTT MT2 MTT group (matrine doses were 7.5,15.0,30.0 mg / kg), MT group in the portal vein and hepatic artery before clipping the main injection of Sophora flavescens Alkali. The NS group was infused with normal saline, the perfusion was resuscitated 70 minutes after blocking the blood supply, and the relevant specimens were collected after 2 hours of reperfusion. The indexes of hepatic function, including serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), lactate dehydrogenase (LDH), and liver homogenate At the same time observe the pathological changes of liver tissue. Results The histopathological examination showed that the degree of hepatocyte injury in MT group was lighter than that in model group, and the MT3 group was the lightest. The liver function index in model group was significantly higher than that in SO group and MT group (all P <0.01) Group was significantly higher than the MT3 group (P <0.05 or P <0.01), that matrine and liver function indicators there is a dose-response relationship. The lowest level of TNF-α in SO group was (54.76 ± 11.32) pg / mg · prot, the highest level of TNF-α in model group was (2 175.67 ± 131.64) pg / mg · prot and the level of MT1 was (1 664.47 ± 109.21) pg / mg · prot, the content of MT2 was (1 561.52 ± 104.52) pg / mg · prot and the content of MT3 was (1 245.17 ± 96.69) pg / mg · prot. The differences between the three groups and the model group were statistically significant (P <0.05). The MT3 group was lower than the MT1 and MT2 (P <0.05). Conclusion Matrine has a protective effect on hepatocyte injury during ischemia / reperfusion, and there is a dose-dependent manner. The mechanism may be related to the inhibition of TNF-α release by matrine.